A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres

Haemophilia

Volumn 9, Issue SUPPL. 1, 2003, Pages 19-26

  Blanchette, Victor S ^a,b   McCready, M ^c   Achonu, C ^d   Abdolell, M ^d   Rivard, G ^e   Manco Johnson, M ^f  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

Factor IX; Factor VIII; Haemophilia A; Haemophilia B; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE;

ADOLESCENT; ARTICLE; CANADA; CENTRAL VEIN; CHILD; CHILD CARE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FOLLOW UP; FREQUENCY ANALYSIS; HEALTH CENTER; HEALTH SURVEY; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PRIORITY JOURNAL; TREATMENT INDICATION; VASCULAR ACCESS;

EID: 0038779248     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.9.s1.12.x     Document Type: Article

References (12)

1. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 25-32.
2. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a longterm follow-up. J Int Med 1997; 241: 395-400.
3. Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998; 79: 932-7.
4. Ljung RCR. Prophylactic treatment in Sweden - over-treatment or optimal model? Haemophilia 1998; 4: 409-12.
5. SAS Institute Inc. SAS®, Version 8.2. Cary, NC: SAS Institute Inc, 2001.
6. Aledort LM, Haschmeyer RH, Pettersson H and the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Int Med 1994; 236: 391-9.
7. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4: 413-7.
8. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
9. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
10. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
11. Ljung R, van den Berg M, Petrini P et al. Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr 1998; 87: 1051-4.
12. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.